细菌性脑膜炎与病毒性脑炎的免疫调节治疗
本文为叙述性综述,检索PubMed和MEDLINE,总结细菌性脑膜炎和病毒性脑炎中免疫调节治疗的证据。随机对照试验和荟萃分析显示辅助糖皮质激素对细菌性脑膜炎的听力损失、神经后遗症和死亡率有益,地塞米松应常规用于社区获得性细菌性脑膜炎;病毒性脑炎中糖皮质激素无明确获益,需新RCT评估早期治疗。
要点
- 社区获得性细菌性脑膜炎应常规使用辅助地塞米松。
- 对乙酰氨基酚无获益,治疗性低温有害,静脉免疫球蛋白证据不足。
- 病毒性脑炎糖皮质激素无明确获益,早期治疗价值待RCT验证。
核心结论
- 辅助地塞米松应常规用于社区获得性细菌性脑膜炎患者。
- 其他免疫调节治疗目前不推荐用于细菌性脑膜炎。
- 病毒性脑炎尚无令人信服的免疫抑制治疗证据。
研究设计与样本
- 叙述性综述,检索PubMed和MEDLINE,纳入随机对照试验、荟萃分析和观察性研究。
主要发现
- 随机对照试验和荟萃分析显示辅助糖皮质激素对细菌性脑膜炎的听力损失、神经后遗症和死亡率有益。
- 观察性研究在临床引入辅助地塞米松后证实了其有益效果。
- 对乙酰氨基酚对细菌性脑膜炎结局无获益,治疗性低温有害,静脉免疫球蛋白证据不足。
- 系统综述和随机对照试验显示糖皮质激素对病毒性脑炎无明确获益。
- 病毒性脑炎中地塞米松治疗通常开始较晚,早期治疗是否获益尚待研究。
关键数值与推荐
- 细菌性脑膜炎:辅助糖皮质激素改善听力损失、神经后遗症和死亡率。
- 病毒性脑炎:糖皮质激素无明确获益,静脉免疫球蛋白证据不足。
临床怎么用
- 社区获得性细菌性脑膜炎患者应常规接受辅助地塞米松治疗。
- 细菌性脑膜炎不推荐使用对乙酰氨基酚、治疗性低温或静脉免疫球蛋白作为免疫调节治疗。
- 病毒性脑炎不推荐常规免疫抑制治疗,早期糖皮质激素治疗需新随机对照试验评估。
局限性
- 病毒性脑炎中地塞米松通常开始较晚,早期治疗是否获益尚不明确。
- 静脉免疫球蛋白治疗病毒性脑炎的证据不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In central nervous system infections, outcome is not only determined by pathogen-mediated injury but also by the host inflammatory response. Inhibition of the immune response has been suggested as an important means of reducing morbidity and mortality. OBJECTIVES: In this review, we summarize the current evidence for immunomodulating treatments in bacterial meningitis and viral encephalitis, discuss the biological rationale underlying these interventions, and identify key knowledge gaps and priorities for future research. SOURCES: For this narrative review, PubMed and MEDLINE were searched using search terms ((bacterial meningitis[MeSH] OR viral encephalitis[MeSH]) AND (immunomodulating treatment OR adjunctive treatment OR corticosteroids) NOT (tubercul∗ OR cryptococc∗ OR vaccine)). CONTENT: For bacterial meningitis, data from randomized clinical trials (RCT) and meta-analyses showed a beneficial effect of adjunctive corticosteroids on hearing loss, neurological sequelae, and mortality. This led to the introduction of adjunctive dexamethasone in clinical practice, after which observational studies confirmed the beneficial effect. Studies on other immunomodulating treatments in bacterial meningitis showed no benefit in the outcome of paracetamol, a harmful effect of therapeutic hypothermia, and insufficient evidence for intravenous immunoglobulins. For viral encephalitis, a systematic review and RCT showed no clear benefit of corticosteroids. Because treatment with dexamethasone was generally started late, it remains an open question whether early corticosteroid treatment could be beneficial. For the treatment of viral encephalitis with intravenous immunoglobulins, insufficient evidence is available to guide clinical practice. IMPLICATIONS: Studies on the modulation of the inflammatory response in bacterial meningitis showed that adjunctive dexamethasone should be routinely used in patients with community-acquired bacterial meningitis. Other immunomodulating treatments in bacterial meningitis are currently not advised. There is no convincing evidence for immunosuppressive treatment in patients with viral encephalitis. Whether early corticosteroid treatment is beneficial in herpes simplex virus encephalitis should be evaluated in a new RCT.
引用
- Brouwer MC, van de Beek D. Immunomodulating treatments for bacterial meningitis and viral encephalitis. Clin Microbiol Infect. 2026. PMID: 42601017. doi:10.1016/j.cmi.2026.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。